003060 — Aprogen Biologics Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩103bn
- KR₩274bn
- KR₩87bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 92,510 | 205,075 | 124,935 | 99,074 | 10,053 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 93,880 | 120,990 | 217,997 | 87,497 | 24,040 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 213,546 | 336,523 | 353,474 | 240,608 | 84,857 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 20,373 | 19,801 | 18,857 | 323,773 | 318,212 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 365,283 | 615,309 | 614,621 | 676,103 | 589,397 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 10,815 | 8,675 | 9,449 | 161,106 | 157,938 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 118,940 | 109,914 | 106,682 | 254,384 | 220,705 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 246,343 | 505,395 | 507,939 | 421,719 | 368,691 |
Total Liabilities & Shareholders' Equity | 365,283 | 615,309 | 614,621 | 676,103 | 589,397 |
Total Common Shares Outstanding |